Longitudinal study of the motor response to Levodopa in Parkinson's disease

Movement Disorders

Volumn 21, Issue 12, 2006, Pages 2116-2121

  Clissold, Benjamin G ^a   McColl, Craig D ^a   Reardon, Katrina R ^a   Shiff, Mark ^a   Kempster, Peter A ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

Levodopa; Motor fluctuations; Parkinson's disease

Indexed keywords

AMANTADINE; BENZATROPINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; LEVODOPA; PERGOLIDE; SELEGILINE;

ADULT; AGED; ARTICLE; BODY EQUILIBRIUM; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DEMENTIA; DISEASE COURSE; DRUG RESPONSE; FEMALE; FOLLOW UP; GAIT; HUMAN; LONGITUDINAL STUDY; MALE; MOTOR ACTIVITY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOTOR ACTIVITY; MOTOR SKILLS; NEUROLOGIC EXAMINATION; PARKINSON DISEASE;

EID: 33846452879     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21126     Document Type: Article

References (18)

1. Reardon KA, Shiff M, Kempster PA. Motor fluctuations in Parkinson's disease: a longitudinal study over 6 years. Mov Disord 1999;14:605-611.
2. McColl CD, Reardon KA, Shiff M, Kempster PA. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease. Mov Disord 2002:6 1227-1234.
3. Nutt JG, Carter JH, Lea ES, Sexton G.J. Evolution of the response to levodopa during the first four years of therapy. Ann Neurol 2002;51:686-693.
4. Hely MA, Morris JGL, Reid WGJ, Trafficante R. Sydney multicentre study of Parkinson's disease: non L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
5. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo Parkinson's disease. Neurology 2001;57:1687-1694.
6. Marras C, McDermott MP, Rochon PA, et al. Survival in Parkinson's disease: thirteen year follow-up of the DATATOP cohort. Neurology 2005;64:87-93.
7. Moro E, Scerrati M, Romito LMA, Roselli R, Tonali P, Albanese A. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 1999;53:85-90.
8. Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996;47:785-788.
9. Shaw KM, Lees AJ, Stern GM. The impact of treatment with L-dopa in Parkinson's disease. Q J Med 1980;195:283-293.
10. Murata M, Mizusawa H, Yamanouchi H, Kanazawa I. Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off. J Neural Transm 1996;103:1177-1185.
11. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-1491.
12. Nutt JG, Carter JC, Woodward WR. The long duration response to L-dopa. Neurology 1995;45:1613-1616.
13. Barbato L, Stocchi F, Monge A, et al. The long-duration action of levodopa may be due to a post-synaptic effect. Clin Neuropharmacol 1997;20:394-401.
14. Ogashara S, Hishakawa Y, Takahashi M, et al. Dopamine metabolism in the central nervous system after discontinuation of L-dopa therapy in patients with Parkinson's disease. J Neurol Sci 1984; 66:151-163.
15. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
16. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Neurology 1996:39;561-573.
17. Zappia M, Oliveri RL, Montesanti R, et al. Loss of long duration response to levodopa over time in PD. Neurology 1999;52:763-767.
18. Nutt JG, Carter JH, Lea ES, Sexton G.J. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 2002; 51:686-693.